Piper Sandler Reiterates Neutral on Pacific Biosciences, Raises Price Target to $3
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $2 to $3.
Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $2 to $3.